Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Nivolumab, pembrolizumab successfully used in Kaposi sarcoma

Galanina et al. Cancer Immunol Res. 2018 Sept 7. doi: 10.1158/2326-6066.CIR-18-0121.

Key clinical point: Checkpoint inhibitor therapy is effective for patients with HIV-associated Kaposi sarcoma.

Major finding: Two-thirds of patients (67%) with HIV-associated Kaposi sarcoma achieved partial or complete remission when treated with immune checkpoint blockade.

Study details: A retrospective study involving nine patients with Kaposi sarcoma treated with either nivolumab or pembrolizumab at the Rebecca and John Moores Cancer Center at the University of California, San Diego, (UCSD) from August 2013 through December 2017.

Disclosures: Authors reported compensation from Incyte, Genentech, Merck, Pfizer, and others.

Source: Galanina et al. Cancer Immunol Res. 2018 Sept 7. doi: 10.1158/2326-6066.CIR-18-0121.

Citation:

Galanina et al. Cancer Immunol Res. 2018 Sept 7. doi: 10.1158/2326-6066.CIR-18-0121.